If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
=== Hank Rizzoli === Hank Rizzoli (Ray Romano) is a photographer who is hired by the Braverman family for a family picture in season four. Sarah ultimately becomes Hank's assistant. While at first he disliked Sarah, the two begin a relationship that has problems as Sarah still has feelings for Mark Cyr. In season five, Hank begins a mentor-mentee relationship with Max and teaches him about photography. After spending time with Max, and reading a book about Asperger syndrome that Adam lent him (after one of Max's outbursts), Hank begins to realize that he shares many social qualities with Max and that he may have Asperger syndrome himself. Hank has a daughter, Ruby, from his previous marriage. When Amber is upset because Ryan York, her ex-fiancé, is involved in an accident, Hank offers to drive Amber the long distance to see Ryan. In season six, after Sarah and Hank move in together, Hank begins to bond with Amber and Drew. He helps Amber assemble her crib and asks Drew to be his best man. Hank and Sarah marry in the series finale.
Oracle Clinical (OC) is a clinical data management system developed by Oracle Corporation for the design of clinical studies, definition of metadata and case report forms (CRFs), data entry and validation, medical coding, and laboratory data management in support of clinical trial operations. It is commonly deployed with Oracle's web-based Remote Data Capture (RDC Onsite) for site investigators to enter and review patient data online.
=== Mass separation === The traditional IM-MS instrument uses a time‐of‐flight (TOF) mass spectrometer interfaced to an IMS. The TOF-MS has many advantages including the high speed of data acquisition and good sensitivity. Since mass spectral data is acquired on a microsecond time scale, multiple mass spectra are collected for each IMS spectrum (acquired on millisecond timescale). The quadrupole mass spectrometer has also been coupled to an IMS, although at a slower scan rate. Other mass spectrometers including the ion trap, Fourier transform ion cyclotron resonance (FT-ICR), or magnetic sector mass spectrometers have also been coupled with different IMS for various applications. Additionally, hybrid mass spectrometers have been interfaced to more than one ion mobility cell for tandem or IMSn–MSm applications.
Sources: en.wikipedia.org
Upon the UK's withdrawal from the European Union, the border in Ireland became the only land border between the UK and the EU. EU single market and UK internal market provisions require certain customs checks and trade controls at their external borders. The Northern Ireland Protocol is intended to protect the EU single market, while avoiding imposition of a 'hard border' that might incite a recurrence of conflict and destabilize the relative peace that has held since the end of the Troubles. Under the Protocol, Northern Ireland is formally outside the EU single market, but EU free movement of goods rules and EU Customs Union rules still apply; this ensures there are no customs checks or controls between Northern Ireland and the rest of the island. In place of an Ireland/Northern Ireland land border, the protocol has created a de facto customs border down the Irish Sea for customs purposes, separating Northern Ireland from the island of Great Britain, to the disquiet of prominent Unionists. To operate the terms of the protocol, the United Kingdom must provide border control posts at Northern Ireland's ports: actual provision of these facilities is the responsibility of Northern Ireland's Department of Agriculture, Environment and Rural Affairs (DAERA). Temporary buildings were put in place for 1 January 2021, but in February 2021, the responsible Northern Ireland minister, Gordon Lyons (DUP), ordered officials to stop work on new permanent facilities and to stop recruiting staff for them.
Some say we should hold elections tomorrow, those have no chances of being free and fair." and added "Ultimately what the long term political leadership is going be, it’s going to be up to Venezuelans." During a conference in Saint Kitts and Nevis with other Caribbean nations on 25 February, United States Secretary of State Marco Rubio said that the US recognizes the need for fair, democratic elections in Venezuela, saying "We do believe that a prosperous, free Venezuela who’s governed by a legitimate government who has the interests of their people in mind could also be an extraordinary partner and asset to many of the countries represented here today." Juan Pablo Guanipa, ally of Machado and political prisoner released during a mass political prisoner release in Venezuela in 2026, said for Spanish newspaper El País, that elections are under way and that Chavismo has lost its ability to impose conditions.
=== Worms === Levamisole was originally used as an anthelmintic to treat worm infestations in both humans and animals. Levamisole works as a nicotinic acetylcholine receptor agonist that causes continued stimulation of the parasitic worm muscles, leading to paralysis. Levamisole has gained prominence among aquarists as an effective treatment for Camallanus roundworm infestations in freshwater tropical fish. Levamisole has been used to treat small ruminant animals since the late 1960s. Levamisole-resistant parasitic worms are common in sheep farms in New Zealand, Uruguay, Paraguay, and Brazil.
Anemia Elevated creatine kinase (CPK) Elevated creatinine Elevated transaminases Hypercapnia Hypercholesterolemia (elevated LDL) Hyperlipidemia Hypoglycemia Hyponatremia Hypoxia Leukopenia Respiratory acidosis
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.